 NEW YORK, March 17, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute UCRI to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia HAP, cystic fibrosis CF, chronic obstructive pulmonary disease COPD and ventilator-associated pneumonia VAP. 